Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 12, 2026, 4:13 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 385–408 of 685 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: CROHN'S DISEASE Clear all
Completed Phase 2 Interventional Results available

A Study of the Safety and Efficacy of Ustekinumab (CNTO 1275) in Participants With Crohn's Disease

NCT00265122
View directory record Official record
Conditions
Crohn Disease
Interventions
Ustekinumab 90 mg, Ustekinumab 4.5 mg/kg, Placebo SC, Placebo IV
Drug
Lead sponsor
Centocor, Inc.
Industry
Eligibility
18 Years and older
Enrollment
131 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2006
U.S. locations
50
States / cities
Scottsdale, Arizona • Anaheim, California • Sacramento, California + 47 more
Source: ClinicalTrials.gov public record
Updated Feb 13, 2014 · Synced Oct 12, 2026, 4:13 PM EDT
Terminated Phase 2 Interventional Results available

A Study of TAK-018 in Preventing the Recurrence of Crohn's Disease After Surgery

NCT03943446
View directory record Official record
Conditions
Crohn Disease
Interventions
TAK-018, TAK-018 Placebo
Drug
Lead sponsor
Takeda
Industry
Eligibility
18 Years and older
Enrollment
34 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2022
U.S. locations
23
States / cities
Little Rock, Arkansas • Los Angeles, California • Aurora, Colorado + 16 more
Source: ClinicalTrials.gov public record
Updated Sep 7, 2023 · Synced Oct 12, 2026, 4:13 PM EDT
Recruiting Not applicable Interventional

Developing a Self-Management Intervention to Improve Health Outcomes for Patients With Inflammatory Bowel Disease

NCT07456566
View directory record Official record
Conditions
Inflammatory Bowel Diseases, Ulcerative Colitis, Crohn Disease
Interventions
Digital self-management program, Standard Care
Behavioral
Lead sponsor
University of Michigan
Other
Eligibility
18 Years and older
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
1
States / cities
Ann Arbor, Michigan
Source: ClinicalTrials.gov public record
Updated Jul 23, 2026 · Synced Oct 12, 2026, 4:13 PM EDT
Completed Phase 3 Interventional

Evaluation of PROCHYMAL® Adult Human Stem Cells for Treatment-resistant Moderate-to-severe Crohn's Disease

NCT00482092
View directory record Official record
Conditions
Crohn's Disease
Interventions
Prochymal®, Placebo
Drug
Lead sponsor
Mesoblast, Inc.
Industry
Eligibility
18 Years to 70 Years
Enrollment
330 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2014
U.S. locations
47
States / cities
Los Angeles, California • San Francisco, California • Wheat Ridge, Colorado + 38 more
Source: ClinicalTrials.gov public record
Updated Mar 11, 2026 · Synced Oct 12, 2026, 4:13 PM EDT
Completed Phase 2 Interventional

Visilizumab for Treatment of Perianal Fistulas in Crohn's Disease

NCT00267709
View directory record Official record
Conditions
Crohn's Disease
Interventions
Visilizumab
Drug
Lead sponsor
Facet Biotech
Industry
Eligibility
18 Years to 70 Years
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2006
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Mar 7, 2012 · Synced Oct 12, 2026, 4:13 PM EDT
Completed Phase 2 Interventional Results available

A Long Term Extension Trial of BI 655066/ABBV-066 (Risankizumab), in Patients With Moderately to Severely Active Crohn's Disease

NCT02513459
View directory record Official record
Conditions
Crohn Disease
Interventions
Risankizumab 600 mg IV, Risankizumab 180 mg SC
Drug
Lead sponsor
AbbVie
Industry
Eligibility
18 Years to 75 Years
Enrollment
65 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2019
U.S. locations
2
States / cities
Chevy Chase, Maryland • Chesterfield, Michigan
Source: ClinicalTrials.gov public record
Updated Apr 24, 2020 · Synced Oct 12, 2026, 4:13 PM EDT
Terminated Phase 4 Interventional

Evaluation of Health Costs and Resource Utilization

NCT01960426
View directory record Official record
Conditions
Ulcerative Colitis, Crohn's Disease
Interventions
Measurement of drug (Adalimumab/Infliximab), Intensify treatment with the existing drug
Other
Lead sponsor
University of Western Ontario, Canada
Other
Eligibility
18 Years and older
Enrollment
51 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2015
U.S. locations
1
States / cities
Denver, Colorado
Source: ClinicalTrials.gov public record
Updated May 13, 2016 · Synced Oct 12, 2026, 4:13 PM EDT
Terminated Phase 2 Interventional

Efficacy of CROWN in Repair and Maintenance of the Intestinal Mucosa in Patients With CD Receiving Anti-TNF Therapy

NCT02793778
View directory record Official record
Conditions
Crohn's Disease
Interventions
CROWN, CROWN Placebo
Drug
Lead sponsor
Prometheus Laboratories
Industry
Eligibility
18 Years to 85 Years
Enrollment
42 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2018
U.S. locations
39
States / cities
Dothan, Alabama • Huntsville, Alabama • Little Rock, Arkansas + 34 more
Source: ClinicalTrials.gov public record
Updated Jun 28, 2019 · Synced Oct 12, 2026, 4:13 PM EDT
Withdrawn Not applicable Interventional

Infliximab, Regulatory T Cells, IL2 and Crohn's Disease

NCT01266785
View directory record Official record
Conditions
Crohn's Disease
Interventions
Infliximab
Drug
Lead sponsor
Oregon Health and Science University
Other
Eligibility
18 Years to 70 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2012
U.S. locations
1
States / cities
Portland, Oregon
Source: ClinicalTrials.gov public record
Updated May 8, 2019 · Synced Oct 12, 2026, 4:13 PM EDT
Completed No phase listed Observational

Follow-Up Phone Calls After Colorectal Surgery

NCT00474097
View directory record Official record
Conditions
Colorectal Surgery, Colorectal Neoplasms, Colitis, Ulcerative, Diverticulitis, Colonic Polyps
Interventions
Not listed
Lead sponsor
University Hospitals Cleveland Medical Center
Other
Eligibility
18 Years to 80 Years
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2007
U.S. locations
1
States / cities
Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Dec 15, 2014 · Synced Oct 12, 2026, 4:13 PM EDT
Completed Phase 3 Interventional

Effect of VSL#3 on Intestinal Permeability in Pediatric Crohn's Disease

NCT00944736
View directory record Official record
Conditions
Crohn's Disease
Interventions
VSL#3, Placebo
Dietary Supplement
Lead sponsor
Children's Mercy Hospital Kansas City
Other
Eligibility
11 Years to 17 Years
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2013
U.S. locations
1
States / cities
Kansas City, Missouri
Source: ClinicalTrials.gov public record
Updated Mar 10, 2014 · Synced Oct 12, 2026, 4:13 PM EDT
Terminated Not applicable Interventional Results available

Evaluate if Response to Infliximab or Adalimumab May be Regained With an Immunomodulator

NCT02413047
View directory record Official record
Conditions
Inflammatory Bowel Disease, Ulcerative Colitis, Crohn's Disease
Interventions
Azathioprine, 6 mercaptopurine, Methotrexate
Drug
Lead sponsor
Indiana University
Other
Eligibility
18 Years to 80 Years
Enrollment
3 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2018
U.S. locations
1
States / cities
Indianapolis, Indiana
Source: ClinicalTrials.gov public record
Updated Nov 4, 2019 · Synced Oct 12, 2026, 4:13 PM EDT
Active, not recruiting No phase listed Observational Accepts healthy volunteers

Combinatorial Single Cell Strategies for a Crohn's Disease Gut Cell Atlas

NCT04113733
View directory record Official record
Conditions
Crohn Disease
Interventions
Sample Collection
Other
Lead sponsor
Vanderbilt University Medical Center
Other
Eligibility
18 Years and older
Enrollment
178 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2027
U.S. locations
1
States / cities
Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Nov 4, 2025 · Synced Oct 12, 2026, 4:13 PM EDT
Completed Phase 2 Interventional

An Efficacy and Safety Evaluation of Inflabloc Cap in the Treatment of Patients With Crohn's Disease

NCT00106314
View directory record Official record
Conditions
Crohn's Disease
Interventions
Dehydroepiandrosterone [DHEA]
Drug
Lead sponsor
Inflabloc Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
75 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2006
U.S. locations
29
States / cities
Huntsville, Alabama • Anaheim, California • San Diego, California + 25 more
Source: ClinicalTrials.gov public record
Updated Oct 19, 2007 · Synced Oct 12, 2026, 4:13 PM EDT
Completed No phase listed Observational

Circadian Misalignment in Inflammatory Bowel Disease

NCT04637399
View directory record Official record
Conditions
Inflammatory Bowel Diseases, Crohn Disease, Ulcerative Colitis
Interventions
Not listed
Lead sponsor
Rush University Medical Center
Other
Eligibility
18 Years to 70 Years
Enrollment
52 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2021
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Jun 30, 2022 · Synced Oct 12, 2026, 4:13 PM EDT
Not listed Phase 3 Interventional

Cimzia Versus Cimzia Plus Azathioprine in the Treatment of Active Crohn's Disease

NCT01817972
View directory record Official record
Conditions
Crohn's Disease
Interventions
Certolizumab pegol, Azathioprine
Biological · Drug
Lead sponsor
Gastroenterology Research of America
Other
Eligibility
18 Years to 70 Years
Enrollment
65 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2014
U.S. locations
1
States / cities
San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Mar 26, 2013 · Synced Oct 12, 2026, 4:13 PM EDT
Recruiting Phase 1Phase 2 Interventional

Low Dose IL-2 for the Treatment of Crohn's Disease

NCT04263831
View directory record Official record
Conditions
Crohn Disease
Interventions
Interleukin-2 (aldesleukin).
Drug
Lead sponsor
Boston Children's Hospital
Other
Eligibility
12 Years to 80 Years
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2027
U.S. locations
3
States / cities
Boston, Massachusetts • New York, New York
Source: ClinicalTrials.gov public record
Updated Aug 3, 2026 · Synced Oct 12, 2026, 4:13 PM EDT
Completed Not applicable Interventional

Relaxation Music for Chronic Pain

NCT06993272
View directory record Official record
Conditions
IBS - Irritable Bowel Syndrome, IBD - Inflammatory Bowel Disease
Interventions
MIndful Jazz, Reggae Stereotypes, Traditional Mindfulness, Pain psychoeducation
Behavioral
Lead sponsor
University of California, Irvine
Other
Eligibility
18 Years and older
Enrollment
120 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2026
U.S. locations
1
States / cities
Orange, California
Source: ClinicalTrials.gov public record
Updated Aug 26, 2026 · Synced Oct 12, 2026, 4:13 PM EDT
Completed Phase 2 Interventional Results available

Study to Evaluate the Efficacy and Safety of Filgotinib in the Treatment of Perianal Fistulizing Crohn's Disease

NCT03077412
View directory record Official record
Conditions
Fistulizing Crohn's Disease
Interventions
Filgotinib, Placebo to match filgotinib
Drug
Lead sponsor
Gilead Sciences
Industry
Eligibility
18 Years to 75 Years
Enrollment
57 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2021
U.S. locations
13
States / cities
Miami, Florida • Orlando, Florida • Tampa, Florida + 10 more
Source: ClinicalTrials.gov public record
Updated Apr 8, 2022 · Synced Oct 12, 2026, 4:13 PM EDT
Completed Not applicable Interventional Results available

A Comprehensive Self-Management Intervention for Individuals With Inflammatory Bowel Disease

NCT05651542
View directory record Official record
Conditions
Inflammatory Bowel Diseases, Ulcerative Colitis, Crohn Disease
Interventions
Comprehensive Self-Management Intervention, Control
Behavioral · Other
Lead sponsor
University of Washington
Other
Eligibility
18 Years to 75 Years
Enrollment
55 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2025
U.S. locations
1
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Sep 28, 2026 · Synced Oct 12, 2026, 4:13 PM EDT
Completed Phase 2 Interventional Results available

Fundamental Modification of the Gut Microbiota in the Treatment of Refractory Crohn's Disease

NCT02765256
View directory record Official record
Conditions
Crohn's Disease
Interventions
Fluconazole, Vancomycin, Neomycin, Ciprofloxacin, Polyethylene Glycol 3350, Promethazine, Fluconazole placebo
Drug
Lead sponsor
University of Pennsylvania
Other
Eligibility
18 Years to 75 Years
Enrollment
8 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2018
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Feb 6, 2024 · Synced Oct 12, 2026, 4:13 PM EDT
Terminated Phase 2 Interventional

VTX958 for the Treatment of Moderately to Severely Active Crohn's Disease

NCT05688852
View directory record Official record
Conditions
Crohn Disease
Interventions
VTX958, VTX958 Placebo
Drug
Lead sponsor
Ventyx Biosciences, Inc
Industry
Eligibility
18 Years to 75 Years
Enrollment
107 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2024
U.S. locations
26
States / cities
Garden Grove, California • Lancaster, California • Kissimmee, Florida + 21 more
Source: ClinicalTrials.gov public record
Updated Jul 3, 2025 · Synced Oct 12, 2026, 4:13 PM EDT
Recruiting Phase 2 Interventional

DB-3Q for the Treatment of Medically Refractory Crohn's Disease

NCT07625293
View directory record Official record
Conditions
Crohn Disease (CD)
Interventions
DB-3Q, Placebo
Biological · Other
Lead sponsor
Direct Biologics, LLC
Industry
Eligibility
18 Years to 75 Years
Enrollment
36 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
1
States / cities
St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Sep 1, 2026 · Synced Oct 12, 2026, 4:13 PM EDT
Terminated Phase 2Phase 3 Interventional Results available

Personalized Infliximab Induction Strategy With Model-informed Dosing in Patients With Crohn's Disease

NCT04974099
View directory record Official record
Conditions
Crohn Disease
Interventions
RoadMAB precision dashboard, Infliximab precision dosing
Device · Drug
Lead sponsor
Children's Hospital Medical Center, Cincinnati
Other
Eligibility
6 Years to 22 Years
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2024
U.S. locations
1
States / cities
Cincinnati, Ohio
Source: ClinicalTrials.gov public record
Updated Mar 11, 2026 · Synced Oct 12, 2026, 4:13 PM EDT